The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Mutations of mitotic checkpoint genes in human cancers
Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/32688 · Cited by 1,486
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
Allelotype of Colorectal Carcinomas
Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y., & White, R. (1989) · Science · doi:10.1126/science.2565047 · Cited by 1,304
Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,126
Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas
Coste, A. D. L., Romagnolo, B., Billuart, P., Renard, C.-A., Buendia, M.-A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8847 · Cited by 1,121
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960
Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
Wang, J., Chenivesse, X., Henglein, B., & Bréchot, C. (1990) · Nature · doi:10.1038/343555a0 · Cited by 671
Miyoshi, Y., Iwao, K., Nagasawa, Y., Aihara, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., & Nakamura, Y. (1998) · PubMed · Cited by 514
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
Nagy, Á., Lánczky, A., Menyhárt, O., & Győrffy, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27521-y · Cited by 1,319
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Self-citationMolecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Zucman-Rossi, J., Jeannot, E., Van Nhieu, J. T., Scoazec, J.-Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., et al. (2006) · Hepatology · doi:10.1002/hep.21068 · Cited by 760
Self-citationGenome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†
Wurmbach, E., Chen, Y., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M., Fiel, I., Thung, S., Mazzaferro, V., Bruix, J., et al. (2007) · Hepatology · doi:10.1002/hep.21622 · Cited by 722
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Wnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., & Zucman-Rossi, J. (2008) · Hepatology · doi:10.1002/hep.22256 · Cited by 684
Self-citationAlcohol and hepatocellular carcinoma
Morgan, T. R., Mandayam, S., & Jamal, M. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.020 · Cited by 625
Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J.-C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 575
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 570
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas
Taniguchi, K., Roberts, L. R., Aderca, I. N., Dong, X., Qian, C., Murphy, L. M., Nagorney, D. M., Burgart, L. J., Roche, P. C., Smith, D. I., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205591 · Cited by 486
Lee, J.-S., Chu, I.-S., Mikaelyan, A., Calvisi, D. F., Heo, J., Reddy, J. K., & Thorgeirsson, S. S. (2004) · Nature Genetics · doi:10.1038/ng1481 · Cited by 475
The toxicology of aflatoxins as a basis for public health decisions
Wild, C. P. (2002) · Mutagenesis · doi:10.1093/mutage/17.6.471 · Cited by 475
Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers
White, B. D., Chien, A. J., & Dawson, D. W. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.001 · Cited by 469
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Khemlina, G., Ikeda, S., & Kurzrock, R. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0712-x · Cited by 464
Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., & Lok, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.035 · Cited by 459
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Durnez, A., Verslype, C., Nevens, F., Fevery, J., Aerts, R., Pirenne, J., Lesaffre, E., Libbrecht, L., Desmet, V, & Roskams, T. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02468.x · Cited by 426
Mechanisms of HBV-related hepatocarcinogenesis
Neuveut, C., Wei, Y., & Buendia, M. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.033 · Cited by 421
New targets of β-catenin signaling in the liver are involved in the glutamine metabolism
Cadoret, A., Ovejero, C., Terris, B., Souil, E., Lévy, L., Lamers, W. H., Kitajewski, J., Kahn, A., & Perret, C. (2002) · Oncogene · doi:10.1038/sj.onc.1206118 · Cited by 410
Viral hepatitis and liver cancer: the case of hepatitis C
Levrero, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209562 · Cited by 404
Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Tavolari, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4797 · Cited by 401
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G. A., Grazi, G. L., Pollutri, D., Croce, C. M., Bolondi, L., & Gramantieri, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0145 · Cited by 396
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378
“Of note, TP53 and CTNNB1 mutations, which are the most frequent drivers of hepatocellular carcinoma in humans, are mutually exclusive 23 (Supplementary Table 1), suggesting that WNT might be suppressed by mutant p53 in hepatocytes.”
Bi-allelic inactivation of TCF1 in hepatic adenomas
Bluteau, O., Jeannot, E., Bioulac-Sage, P., Marqués, J. M., Blanc, J.-F., Bui, H., Beaudoin, J.-C., Franco, D., Balabaud, C., Laurent-Puig, P., et al. (2002) · Nature Genetics · doi:10.1038/ng1001 · Cited by 353
Self-citationWNT/β-catenin signaling in the development of liver cancers
He, S., & Tang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110851 · Cited by 351
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 339
Infectious agents and cancer: criteria for a causal relation
Pagano, J. S., Blaser, M., Buendia, M.-A., Damania, B., Khalili, K., Raab-Traub, N., & Roizman, B. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.009 · Cited by 337
Liver stem cells and hepatocellular carcinoma†
Mishra, L., Banker, T., Murray, J., Byers, S., Thenappan, A., He, A. R., Shetty, K., Johnson, L., & Reddy, E. P. (2009) · Hepatology · doi:10.1002/hep.22704 · Cited by 333
Colnot, S., Decaens, T., Niwa-Kawakita, M., Godard, C., Hamard, G., Kahn, A., Giovannini, M., & Perret, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404761101 · Cited by 328
Rebouissou, S., Franconi, A., Calderaro, J., Letouzé, E., Imbeaud, S., Pilati, C., Nault, J., Couchy, G., Laurent, A., Balabaud, C., et al. (2016) · Hepatology · doi:10.1002/hep.28638 · Cited by 327
Self-citationSeitz, H. K., & Stickel, F. (2006) · Biological Chemistry · doi:10.1515/bc.2006.047 · Cited by 325
Genetic mechanisms of hepatocarcinogenesis
Feitelson, M. A., Sun, B., Lale Satiroglu Tufan, N., Liu, J., Pan, J., & Lian, Z. (2002) · Oncogene · doi:10.1038/sj.onc.1205434 · Cited by 322
Genetics of hepatocellular tumors
Laurent-Puig, P., & Zucman-Rossi, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209547 · Cited by 317
Self-citationMolecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma
Jeng, Y.-M., Peng, S.-Y., Lin, C.-Y., & Hsu, H.-C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1057-03 · Cited by 304
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 304
Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.001 · Cited by 294
Zucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C. (2007) · Oncogene · doi:10.1038/sj.onc.1209824 · Cited by 256
Self-citationFunctional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma
Merle, P., de la Monte, S., Kim, M., Herrmann, M., Tanaka, S., Von Dem Bussche, A., Kew, M. C., Trepo, C., & Wands, J. R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.009 · Cited by 249
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
Bengochea, A., de Souza, M. M., Lefrançois, L., Le Roux, E., Galy, O., Chemin, I., Kim, M., Wands, J. R., Trepo, C., Hainaut, P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604422 · Cited by 215
“…of the Wnt/b-catenin pathway, due or unrelated to b-catenin gene mutation, is a common event in hepatocarcinogenesis and is associated with the clinical and pathological features of the disease (Hsu et al, 2000; Devereux et al, 2001; Laurent-Puig et al, 2001; Wong et al, 2001; Inagawa et al, 2002).”
Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162
Renard, C.-A., Labalette, C., Armengol, C., Cougot, D., Wei, Y., Cairo, S., Pineau, P., Neuveut, C., de Reyniès, A., Dejean, A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2344 · Cited by 157
“It suggests that the Wnt/h-catenin pathway was activated through other means, such as overexpression of Frizzled-7 or loss-of-function mutations of Axin ( 9 ).”
BackgroundGaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Bonnet, S., Gaujoux, S., Launay, P., Baudry, C., Chokri, I., Ragazzon, B., Libé, R., René-Corail, F., Audebourg, A., Vacher-Lavenu, M.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1885 · Cited by 133
Ovejero, C., Cavard, C., Périanin, A., Hakvoort, T., Vermeulen, J., Godard, C., Fabre, M., Chafey, P., Suzuki, K., Romagnolo, B., et al. (2004) · Hepatology · doi:10.1002/hep.20286 · Cited by 118
p53 mutation as a source of aberrant β-catenin accumulation in cancer cells
Cagatay, T., & Ozturk, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205919 · Cited by 110
“%) aMainland China and Hong Kong, bAustralia, North America, Singapore, South Korea, Taiwan, Thailand, or unidentifiable origin. b-catenin data is a combination of the data presented here (data for Africa and part of China), and those compiled from references Devereux et al., 2001, Wong et al., 2001 (for China); Miyos…”
BackgroundMethodInfluentialCalvisi, D. F., Factor, V. M., Ladu, S., Conner, E. A., & Thorgeirsson, S. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.014 · Cited by 100
Hale, G., Liu, X., Hu, J., Xu, Z., Che, L., Solomon, D., Tsokos, C., Shafizadeh, N., Chen, X., Gill, R., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.122 · Cited by 73
“Inactivation of the AXIN1 gene has been reported in 5–15% of hepatocellular carcinoma (19, 37).”
Background
Metadata
- Authors
- Laurent–Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., Monges, G., Thomas, G., Bioulac–Sage, P., & Zucman–Rossi, J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2001-06
- Volume
- 120
- Issue
- 7
- Pages
- 1763-1773
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2118231569
- Cited by
- 582
- References
- 34
- FWCI
- 19.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.